Some rheumatologists question the depth of research and the approval’s implications for patient access
The Rheumatologist: May 2010
Information on New Approvals and Medication Safety
Strides in recognition and management of joint hypermobility syndrome
Evolving model has implications for novel therapies
Did a busy practice prevent you from getting to Chicago in April for the ACR’s 2010 State-of-the-Art Clinical Symposium? Still want the latest news and education in rheumatology? Or, did you attend the meeting and want to revisit some of your favorite sessions? Nineteen general-session presentations from the symposium are now available on ACR’s SessionSelect, allowing you to tailor your learning experience to your educational needs without leaving your home or office, saving time and money.
The current health system places increasing pressure on physicians and their practices to find new and innovative ways to maximize reimbursement through the implementation of programs and workflows that ensure the delivery of higher quality care—all while the ever-increasing needs of the patient population are placing a greater demand on physician time.
Under the ACR’s new strategic plan, the mission of the ACR is advancing rheumatology, and the new vision is to enhance the value and impact of rheumatology in a changing healthcare environment. These cannot be achieved without the time, effort, talent, and experience of its volunteer leadership and committee members.
May’s Coding Answer
May’s Coding Challenge
Robert McLean, DSc, MPH, is an assistant research scientist at the Hebrew SeniorLife Institute for Aging Research in Boston, and his primary research interests lie in the epidemiology of osteoporosis and related fractures. After working in epidemiology for over 10 years, Dr. McLean recently established himself as an independent investigator without significant prior research experience, thanks to the help of an REF research award designed specifically for early career investigators.
With the rapid expansion of new classes of medications, clinical practice has changed dramatically, and rheumatology health professionals must have a fundamental knowledge of immunology and the mechanisms of action of the biologic agents that have emerged with this expansion. Familiarity with the predrug screening recommended for biologic agents and the appropriate safety and disease monitoring necessary when a person uses these products is essential for the best patient outcomes. Additionally, being able to obtain drug plan authorization for use of biologics and being able to educate patients and their families or support team members about the financial considerations of these drugs helps to ensure best rheumatology practice.
A study recently published in Arthritis & Rheumatism found that a cohort of patients from multiethnic backgrounds who all had rheumatoid arthritis (RA) had nearly double the rate of depressive symptoms compared with middle-class white patients with RA.1 The study also examined predictors of depression, and concluded that physical disability—not acute disease activity—is the principal predictor of depression in patients with RA.
Building on the success of last year’s attendance-breaking ACR/ARHP Annual Scientific Meeting, the ACR and ARHP planning committees are offering an annual meeting program that that will exceed expectations. Plan to join your colleagues in Atlanta November 6–11 to benefit from both high-quality rheumatology education and a unique blend of cosmopolitan experiences and cultural charm—all of which will quench an array of intellectual, cultural, and culinary appetites.
Comments on the Medicare decision to eliminate consultation codes
Is it time to advise our athletes to play it safe?
Even though the law was passed, the work of reform is just beginning
Use motivational interviewing to facilitate behavior change for your clients